X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Cadila Healthcare with Dishman Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CADILA HEALTHCARE vs DISHMAN PHARMA - Comparison Results

CADILA HEALTHCARE    Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

DISHMAN PHARMA 
   Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CADILA HEALTHCARE DISHMAN PHARMA CADILA HEALTHCARE/
DISHMAN PHARMA
 
P/E (TTM) x 32.4 25.1 128.9% View Chart
P/BV x 6.4 3.3 191.5% View Chart
Dividend Yield % 0.7 0.7 110.5%  

Financials

 CADILA HEALTHCARE   DISHMAN PHARMA
EQUITY SHARE DATA
    CADILA HEALTHCARE
Mar-17
DISHMAN PHARMA
Mar-16
CADILA HEALTHCARE/
DISHMAN PHARMA
5-Yr Chart
Click to enlarge
High Rs460374 122.9%   
Low Rs305129 236.6%   
Sales per share (Unadj.) Rs92.1197.8 46.6%  
Earnings per share (Unadj.) Rs14.821.2 69.9%  
Cash flow per share (Unadj.) Rs18.534.7 53.2%  
Dividends per share (Unadj.) Rs3.202.00 160.0%  
Dividend yield (eoy) %0.80.8 105.3%  
Book value per share (Unadj.) Rs68.0179.9 37.8%  
Shares outstanding (eoy) m1,023.7480.69 1,268.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.21.3 326.4%   
Avg P/E ratio x25.811.9 217.5%  
P/CF ratio (eoy) x20.77.2 285.6%  
Price / Book Value ratio x5.61.4 402.2%  
Dividend payout %21.69.4 229.0%   
Avg Mkt Cap Rs m391,58120,306 1,928.4%   
No. of employees `00016.90.8 2,033.2%   
Total wages/salary Rs m15,0025,355 280.2%   
Avg. sales/employee Rs Th5,594.519,252.7 29.1%   
Avg. wages/employee Rs Th890.16,459.5 13.8%   
Avg. net profit/employee Rs Th899.92,064.1 43.6%   
INCOME DATA
Net Sales Rs m94,29515,961 590.8%  
Other income Rs m1,286265 484.6%   
Total revenues Rs m95,58116,226 589.1%   
Gross profit Rs m19,0364,103 463.9%  
Depreciation Rs m3,7501,091 343.8%   
Interest Rs m450944 47.6%   
Profit before tax Rs m16,1222,334 690.9%   
Minority Interest Rs m3380-   
Prior Period Items Rs m01 0.0%   
Extraordinary Inc (Exp) Rs m-30-   
Tax Rs m1,289624 206.7%   
Profit after tax Rs m15,1681,711 886.4%  
Gross profit margin %20.225.7 78.5%  
Effective tax rate %8.026.7 29.9%   
Net profit margin %16.110.7 150.0%  
BALANCE SHEET DATA
Current assets Rs m60,22311,018 546.6%   
Current liabilities Rs m53,0589,517 557.5%   
Net working cap to sales %7.69.4 80.8%  
Current ratio x1.11.2 98.0%  
Inventory Days Days70110 63.2%  
Debtors Days Days8835 253.1%  
Net fixed assets Rs m72,98416,304 447.6%   
Share capital Rs m1,024161 634.4%   
"Free" reserves Rs m68,57612,907 531.3%   
Net worth Rs m69,60014,516 479.5%   
Long term debt Rs m24,6844,189 589.2%   
Total assets Rs m152,20729,805 510.7%  
Interest coverage x36.83.5 1,061.0%   
Debt to equity ratio x0.40.3 122.9%  
Sales to assets ratio x0.60.5 115.7%   
Return on assets %10.38.9 115.2%  
Return on equity %21.811.8 184.9%  
Return on capital %17.917.5 102.3%  
Exports to sales %024.8 0.0%   
Imports to sales %03.7 0.0%   
Exports (fob) Rs mNA3,956 0.0%   
Imports (cif) Rs mNA596 0.0%   
Fx inflow Rs m21,2804,952 429.8%   
Fx outflow Rs m10,874697 1,560.6%   
Net fx Rs m10,4064,255 244.6%   
CASH FLOW
From Operations Rs m13,4952,786 484.3%  
From Investments Rs m-29,103-1,529 1,903.5%  
From Financial Activity Rs m23,158-941 -2,460.7%  
Net Cashflow Rs m7,556316 2,388.1%  

Share Holding

Indian Promoters % 74.8 61.4 121.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 8.3 3.7 224.3%  
FIIs % 5.9 12.7 46.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 11.0 22.1 49.8%  
Shareholders   44,069 46,261 95.3%  
Pledged promoter(s) holding % 0.0 35.8 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CADILA HEALTHCARE With:   CIPLA  PFIZER  ALKEM LABORATORIES  SHASUN PHARMA  SANOFI INDIA  

Compare CADILA HEALTHCARE With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Day in Red; Realty Stocks Top Losers(Closing)

After opening the day in green, share markets in India witnessed volatile trading activity throughout the day and ended the day on a dull note.

Related Views on News

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

Is it Wise to Ignore Bitcoins?(The 5 Minute Wrapup)

Jan 4, 2018

While investing in bitcoins, it would make sense to treat it as another asset class and decide accordingly.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Resolutions for 2018 - by others(The Honest Truth)

Jan 8, 2018

Ten quirky new year resolutions. Guess by whom?

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

CADILA HEALTHCARE SHARE PRICE


Jan 16, 2018 (Close)

TRACK CADILA HEALTHCARE

  • Track your investment in CADILA HEALTHCARE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON CADILA HEALTHCARE

CADILA HEALTHCARE - SHASUN PHARMA COMPARISON

COMPARE CADILA HEALTHCARE WITH

MARKET STATS